Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Juerg Lehmann

Showing results (1-10 of 13) with videos related to

Pageof 2
Sort By:
Pharmaceutical Patent Analyst|November 19, 2013
GPR119 agonists 2009-2011Daniel J Buzard, Juerg Lehmann, Sangdon Han, et al.
Expert Opinion on Therapeutic Patents|September 29, 2009
GPR119 agonists for the treatment of type 2 diabetesRobert M Jones, James N Leonard, Daniel J Buzard, et al.
Pharmaceuticals (Basel, Switzerland)|February 27, 2026
OPLE: Drug Discovery Platform Combining 2D Similarity with AI to Predict Off-Target LiabilitiesSarah E Biehn, Juerg Lehmann, Christoph Mueller, et al.
Structure (London, England : 1993)|November 4, 2015
Mutation-Guided Unbiased Modeling of the Fat Sensor GPR119 for High-Yield Agonist ScreeningChristoffer Norn, Maria Hauge, Maja S Engelstoft, et al.
Future Medicinal Chemistry|February 19, 2024
BioPrint meets the AI age: development of artificial intelligence-based ADMET models for the drug-discovery platform SAFIRESarah E Biehn, Luis Miguel Goncalves, Juerg Lehmann, et al.
Bioorganic & Medicinal Chemistry Letters|December 24, 2014
Design and synthesis of new tricyclic indoles as potent modulators of the S1P1 receptorDaniel J Buzard, Thomas O Schrader, Xiuwen Zhu, et al.
Journal of Medicinal Chemistry|May 14, 2025
Diazepine Agonists of the 5-HT<sub>2C</sub> Receptor with Unprecedented Selectivity: Discovery of Bexicaserin (LP352)Albert Ren, Xiuwen Zhu, Juerg Lehmann, et al.
Bioorganic & Medicinal Chemistry Letters|August 12, 2009
Solubilized phenyl-pyrazole ureas as potent, selective 5-HT(2A) inverse-agonists and their application as antiplatelet agentsPeter I Dosa, Sonja Strah-Pleynet, Honnappa Jayakumar, et al.
Bioorganic & Medicinal Chemistry Letters|January 24, 2012
Discovery of a second generation agonist of the orphan G-protein coupled receptor GPR119 with an improved profileGraeme Semple, Juerg Lehmann, Amy Wong, et al.
Bioorganic & Medicinal Chemistry Letters|August 5, 2014
Discovery and optimization of 5-fluoro-4,6-dialkoxypyrimidine GPR119 agonistsDaniel J Buzard, Sun Hee Kim, Juerg Lehmann, et al.
Pageof 2

Showing results (1-10 of 13) with videos related to

Sort By:
Pageof 2
Pharmaceutical Patent Analyst|November 19, 2013
GPR119 agonists 2009-2011Daniel J Buzard, Juerg Lehmann, Sangdon Han, et al.
Expert Opinion on Therapeutic Patents|September 29, 2009
GPR119 agonists for the treatment of type 2 diabetesRobert M Jones, James N Leonard, Daniel J Buzard, et al.
Pharmaceuticals (Basel, Switzerland)|February 27, 2026
OPLE: Drug Discovery Platform Combining 2D Similarity with AI to Predict Off-Target LiabilitiesSarah E Biehn, Juerg Lehmann, Christoph Mueller, et al.
Structure (London, England : 1993)|November 4, 2015
Mutation-Guided Unbiased Modeling of the Fat Sensor GPR119 for High-Yield Agonist ScreeningChristoffer Norn, Maria Hauge, Maja S Engelstoft, et al.
Future Medicinal Chemistry|February 19, 2024
BioPrint meets the AI age: development of artificial intelligence-based ADMET models for the drug-discovery platform SAFIRESarah E Biehn, Luis Miguel Goncalves, Juerg Lehmann, et al.
Bioorganic & Medicinal Chemistry Letters|December 24, 2014
Design and synthesis of new tricyclic indoles as potent modulators of the S1P1 receptorDaniel J Buzard, Thomas O Schrader, Xiuwen Zhu, et al.
Journal of Medicinal Chemistry|May 14, 2025
Diazepine Agonists of the 5-HT<sub>2C</sub> Receptor with Unprecedented Selectivity: Discovery of Bexicaserin (LP352)Albert Ren, Xiuwen Zhu, Juerg Lehmann, et al.
Bioorganic & Medicinal Chemistry Letters|August 12, 2009
Solubilized phenyl-pyrazole ureas as potent, selective 5-HT(2A) inverse-agonists and their application as antiplatelet agentsPeter I Dosa, Sonja Strah-Pleynet, Honnappa Jayakumar, et al.
Bioorganic & Medicinal Chemistry Letters|January 24, 2012
Discovery of a second generation agonist of the orphan G-protein coupled receptor GPR119 with an improved profileGraeme Semple, Juerg Lehmann, Amy Wong, et al.
Bioorganic & Medicinal Chemistry Letters|August 5, 2014
Discovery and optimization of 5-fluoro-4,6-dialkoxypyrimidine GPR119 agonistsDaniel J Buzard, Sun Hee Kim, Juerg Lehmann, et al.
Pageof 2